Basal Cell Carcinoma - Pipeline Review, H1 2017
Basal Cell Carcinoma - Pipeline Review, H1 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2017, provides an overview of the Basal Cell Carcinoma (Oncology) pipeline landscape.
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 3 and 6 respectively.
Basal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2017, provides an overview of the Basal Cell Carcinoma (Oncology) pipeline landscape.
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 3 and 6 respectively.
Basal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Basal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development
Biosceptre International Ltd
BLR Bio LLC
Cannabis Science Inc
Genextra Spa
Ignyta Inc
Laboratories Ojer Pharma SL
MediGene AG
Merck & Co Inc
Provectus Biopharmaceuticals Inc
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Transgene SA
Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-010t - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLR-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-S/BCC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTATI-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAC-060 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oshadi D + Oshadi R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patidegib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PV-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-2810 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sinecatechins - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taladegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-1042 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products
Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones
Featured News & Press Releases
Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma
Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development
Biosceptre International Ltd
BLR Bio LLC
Cannabis Science Inc
Genextra Spa
Ignyta Inc
Laboratories Ojer Pharma SL
MediGene AG
Merck & Co Inc
Provectus Biopharmaceuticals Inc
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Transgene SA
Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-010t - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLR-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-S/BCC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTATI-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAC-060 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oshadi D + Oshadi R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patidegib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PV-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-2810 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sinecatechins - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taladegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-1042 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products
Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones
Featured News & Press Releases
Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma
Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Ltd, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by BLR Bio LLC, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra Spa, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ignyta Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma SL, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Redx Pharma Plc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H1 2017
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Ltd, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by BLR Bio LLC, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra Spa, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ignyta Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma SL, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Redx Pharma Plc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H1 2017
LIST OF FIGURES
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
Biosceptre International Ltd
BLR Bio LLC
Cannabis Science Inc
Genextra Spa
Ignyta Inc
Laboratories Ojer Pharma SL
MediGene AG
Merck & Co Inc
Provectus Biopharmaceuticals Inc
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Transgene SA
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
Biosceptre International Ltd
BLR Bio LLC
Cannabis Science Inc
Genextra Spa
Ignyta Inc
Laboratories Ojer Pharma SL
MediGene AG
Merck & Co Inc
Provectus Biopharmaceuticals Inc
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Transgene SA
